UK Wants European Court's View On Paroxetine Pay-For-Delay Case
Executive Summary
A referral in the long-running paroxetine pay-for-delay case will see the Court of Justice of the EU give preliminary rulings on a number of competition issues such as abuse of a dominant position, the relevant product market, and restrictions of competition by object and by effect.
You may also be interested in...
EU Servier Court Ruling 'Reduces Competition Law Risks For Pharma'
The EU’s General Court judgement in the Servier pay-for-delay case will put more pressure on competition authorities to show evidence of alleged abuse of a dominant position.
Pharma Cases Show How Brexit Could Hit Alignment Of UK & EU Competition Law
Brexit could result in a gradual divergence of competition law decisions in the UK and the EU, according to one law firm, which already detects evidence of this in recent competition cases.
Concordia Names Six Drugs Targeted By UK Competition Inquiry
Concordia has announced that six more of its medicines are involved in the UK competition inquiry. One law firm says the announcement further underlines the Competition and Markets Authority’s determination to root out anticompetitive practices in the pharma area.